2023-2025 News Items

In-Depth Interview with Chairman Tse-Wen Chang: Leading T-E Meds in Advancing ADC Technology

Join our presentation at the 16th Annual World ADC – San Diego 2025!

T-E Meds Shortlisted for World ADC Awards, Showcasing Global Recognition of Its Innovative Platform and Pipeline

Congratulations! T-E Meds is proud to be recognized by the Ministry of Economic Affairs as a certified Biotech & Pharmaceutical Company!

Join our presentation at the Asia BIO Innovation Summit 2025

TE-1146 drug development was selected as a significant case of the Center for Drug Evaluation (CDE), Taiwan

Join our presentation at the BIO Asia-Taiwan 2025 Conference

T-E Meds and Asymchem Join Forces to Drive Innovation in Drug Conjugates and Explore the Future of Targeted Therapeutics

Join our presentation at the World ADC Asia 2025 Conference

T-E Meds and Orient EuroPharma Forge Licensing Agreement for TE-1146

Join our presentation at the World ADC San Diego 2024

Join our presentation at the BIO Asia-Taiwan 2024 Conference

Join our presentation at the World ADC Asia 2024 Conference

Our latest research result is published in Advanced Science

Join Our presentation at The BiG ADC/XDC Conference

Join Our presentation at The 5th ADC Development Summit

Join Our presentation at the prestigious J.P. Morgan Healthcare Conference

FDA approves Xolair as first and only medicine for children and adults with one or more food allergies

Join our presentation at the World ADC San Diego 2023!

T-E Meds has received an invitation to present the latest ADC technology platform at the World ADC San Diago conference

T-E Meds and CHO Pharma offer complementary technologies to form a robust ADC development platform

Our latest research result is published in J. Med. Chem.

Immunwork links future to T-E Meds, promoting ADC, ARC platforms development

BIO 2023 International Convention in Boston